3Austin HA,Muenz LR,Joyce KM,et al.Prognosic factors in lupus nephritis.Contribution of renal histologic data.Am J Med,1983,75:382-391.
4Esdaile JM JL,MacKenzie T,Kashgarian M,et al.The benefit of early treatment with immunosuppressive agents in lupus nephritis.J Rheumatol,1994,21:2046-2051.
5Houssiau FA VC,D'Cruz D,Sebastiani GD,et al.Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis:lessons from long-term followup of patients in the EuroLupus Nephritis Trial.Arthritis Rheum,2004,50:3934-3940.
7Flanc RS,Roberts MA,Strippoli GF,et al.Treatment of diffuse proliferative lupus nephritis:a meta-analysis of randomized controlled trials.Am J Kidney Dis,2004,43:197-208.
8Grootscholten CLG,Hagen EC,van den Wall Bake AW,et al.Dutch working party on systemic lupus erythematosus.Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis.A randomized controlled trial.Kidney Iht,2006,70:732-742.
9Bertsias G,Ioannidis JP,Boletis J,et al.EULAR recommendations for the management of systemic lupus erythematosus.Report of a task force of the EULAR standing committee for international clinical studies including therapeutics.Ann Rheum Dis,2008,67:195-205.
10Chan TM,Tse KC,Tang CS,et al.Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.J Am Soc Nephrol,2005,16:1076-1084.
